Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
复制标题
DOI：
10.1007/s12325-018-0784-z
复制
发表时间：
2018-10
影响因子：
3.8
通讯作者：
Marshall JL
中科院分区：
文献类型：
--
作者：
Kim S;Signorovitch JE;Yang H;Patterson-Lomba O;Xiang CQ;Ung B;Parisi M;Marshall JL
白蛋白结合型紫杉醇加吉西他滨 (nab-P + G) 和 FOLFIRINOX (FFX) 是胰腺转移性腺癌 (MPAC) 最常见的一线 (1L) 疗法，但有关其疗效比较的真实数据有限。这项回顾性队列研究比较了 1L nab-P + G 与 FFX 的总体疗效和安全性以及特定治疗序列下的疗效和安全性。 215 名美国医生审查了病历，提供了 2015 年 4 月 1 日至 2015 年 12 月 31 日期间开始使用 nab-P + G 或 FFX 1L 治疗的 MPAC 患者的信息。研究结果为总生存期 (OS) 和耐受性。使用 Kaplan-Meier 曲线和调整后的 Cox 比例风险模型比较 OS。总共审查了 654 份病历，包括分别开始接受 nab-P + G 和 FFX 作为 1L MPAC 治疗的 337 名和 317 名患者的病历。与 FFX 启动的患者相比，nab-P + G 启动的患者年龄较大，ECOG ≤ 1 的可能性较小，并且有更多的合并症。对于 nab-P + G 和 FFX 启动的患者，中位 OS (mOS) 分别为 12.1 和 13.8 个月（HR = 0.99，P = 0.96）。在ECOG ≤ 1的患者中，mOS分别为14.1和13.7个月（HR = 1.00，P = 0.99）。在 1L nab-P + G 和 FFX 患者中，36.1% 和 41.3% 接受 2L 治疗，mOS 分别为 16.3 和 16.6 个月（HR = 1.04，P = 0.76）。 FFX 组中腹泻、疲劳、粘膜炎以及恶心和呕吐的发生率显着高于 nab-P + G 组。总体而言，接受 1L nab-P + G 或 FFX 的患者与接受积极 2L 治疗的患者的真实生存率相似。此外，与 FFX 相比，nab-P + G 的常见 AE 发生率显着降低。新基公司。本文的在线版本 (10.1007/s12325-018-0784-z) 包含补充材料，可供授权用户使用。
nab-Paclitaxel plus gemcitabine (nab-P + G) and FOLFIRINOX (FFX) are among the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas (MPAC), but real-world data on their comparative effectiveness are limited. This retrospective cohort study compared the efficacy and safety of 1L nab-P + G versus FFX, overall and under specific treatment sequences. Medical records were reviewed by 215 US physicians who provided information on MPAC patients who initiated 1L therapy with nab-P + G or FFX between April 1, 2015 and December 31, 2015. Study outcomes were overall survival (OS) and tolerability. OS was compared using Kaplan–Meier curves and adjusted Cox proportional hazards models. In total, 654 medical records were reviewed, including those of 337 and 317 patients initiated on nab-P + G and FFX as 1L MPAC therapy, respectively. nab-P + G-initiated patients were older, less likely to have ECOG ≤ 1, and had more comorbidities than FFX-initiated patients. Median OS (mOS) was 12.1 and 13.8 months for nab-P + G- and FFX-initiated patients, respectively (HR = 0.99, P = 0.96). Among patients with ECOG ≤ 1, mOS was 14.1 and 13.7 months, respectively (HR = 1.00, P = 0.99). Among patients with 1L nab-P + G and FFX, 36.1% and 41.3% received 2L therapy and experienced mOS of 16.3 and 16.6 months, respectively (HR = 1.04, P = 0.76). The rates of diarrhea, fatigue, mucositis, and nausea and vomiting were significantly higher in the FFX than nab-P + G cohort. The real-world survival was similar between patients receiving 1L nab-P + G or FFX both overall and among patients who received active 2L treatments. In addition, nab-P + G was associated with significantly lower rates of common AEs compared with FFX. Celgene. The online version of this article (10.1007/s12325-018-0784-z) contains supplementary material, which is available to authorized users.
登录
查看更多内容
DOI：
10.6004/jnccn.2017.0131
发表时间：
2017-08-01
影响因子：
13.4
作者：
Tempero, Margaret A.;Malafa, Mokenge P.;Darlow, Susan
通讯作者：
Darlow, Susan
影响因子：
3.7
作者：
Chan, Kelvin;Shah, Keya;Ko, Yoo-Joung
通讯作者：
Ko, Yoo-Joung
影响因子：
4.3
作者：
Bilici, Ahmet
通讯作者：
Bilici, Ahmet
影响因子：
168.9
作者：
Wang-Gillam, Andrea;Li, Chung-Pin;Chen, Li-Tzong
通讯作者：
Chen, Li-Tzong
DOI：
10.1056/nejmoa1304369
发表时间：
2013-10-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Von Hoff DD;Ervin T;Arena FP;Chiorean EG;Infante J;Moore M;Seay T;Tjulandin SA;Ma WW;Saleh MN;Harris M;Reni M;Dowden S;Laheru D;Bahary N;Ramanathan RK;Tabernero J;Hidalgo M;Goldstein D;Van Cutsem E;Wei X;Iglesias J;Renschler MF
通讯作者：
Renschler MF